We further analysed the role of pERK1/2 in the maintenance of BC axiopodia by treating WT mice with the MEK1/2 inhibitor PD325901 via daily intraperitoneal injections (10 mg kg−1). This evidence concerns the gene MAP2K1 and breast cancer.